RetaMaps

Sol Endocrinology, PLLC

Sol Endocrinology, PLLC · 4300 N CENTRAL EXPY STE 255 · Dallas, TX 75206

4.5· 94 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss
  • Endocrine / metabolic care

About this practice

Sol Endocrinology is an endocrinology practice in Dallas, Texas, where Erin D. Roe, MD, who its website says is board-certified in internal medicine and in endocrinology, diabetes and metabolism, sees patients. The site says it treats diabetes, thyroid disease, PCOS and hormone imbalance, offers cash-pay pricing for patients without insurance, and discusses the role of hormones in weight regulation. Weight-loss care and telehealth are also listed. Google shows a 4.5-star rating across 94 reviews since 2021, with 29 in the past year; reviewers mention the staff and the physician's knowledge most, and 10 mention a caring approach.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice website—
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.5
Google rating · 94 reviews
29
reviews in the past year (avg ★ 4.6)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-21. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.5 across 94 Google reviews. Of the 91 reviews we analyzed, 78 (86%) are positive (4–5★) and 11 (12%) are negative (1–2★).

What patients like

  • Friendly, helpful staff20 reviews
  • Knowledgeable, professional providers16 reviews
  • Feeling listened to10 reviews
  • Easy scheduling and communication6 reviews

Common complaints

  • Billing, pricing or insurance problems4 of 11 negative
  • Scheduling or communication problems3 of 11 negative
  • Felt rushed or unheard2 of 11 negative
5★
77
4★
1
3★
2
2★
2
1★
9

Most recent Google reviews

Haley A.★★★★★2026-09-21

Dr. Roe is an exceptional physician! She is knowledgeable and an incredibly clever diagnostician. Her office is lovely and clean and very peaceful. The receptionist and scheduler, Jolene, is incredibly personable and clever. Dailey, the nurse, is also knowledgeable and exceptional at her job. Everyone is quite warm, and I highly recommend this office.

Tanya C.★★★★★2026-08-10

Undivided attention from Dr. Roe and her staff for a full hour! She was so knowledgeable about my conditions and open to all my questions. Very excited to be working with Sol Endocrinology!

Cheryl★★★★★2026-08-05

Dr Roe and her staff are absolutely amazing!

Misti W.★★★★★2026-07-31

From reception, to vitals/bloodwork, to consultation with Dr. Roe, every part of the experience is handled with care. Everyone is attentive, efficient and kind. I feel appreciated and valued each time I visit.

Cynthia A.★★★★★2026-07-31

Dr Roe and her team are amazing!! Best money I’ve ever spent. Dr Roe listens and finds solutions for you. You are not just another body in the next room waiting for 10 mins of dr time. She is a gem and I recommend her highly.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Dallas

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs